Synergistic and persistent interaction between the D2 agonist, bromocriptine, and the D1 selective agonist, CY 208–243

Postsynaptic Supersensitivity after 6‐Hydroxy‐dopamine Induced Degeneration of the Nigro‐striatal Dopamine System

1971 • 1,922 citations

The central effects of a novel dopamine agonist

1978 • 646 citations

Bromocriptine in Parkinsonism

1974 • 311 citations

Evidence that L-dopa-induced rotational behavior is dependent on both striatal and nigral mechanisms

1989 • 197 citations

Synergistic effects of D1 and D2 dopamine agonists on turning behaviour in rats

1986 • 178 citations

Dopamine receptor interactions: some implications for the treatment of Parkinson's disease

1992 • 154 citations

Stereotyped behaviour in response to the selective D-2 dopamine receptor agonist RU 24213 is enhanced by pretreatment with the selective D-1 agonist SK&F 38393

1986 • 130 citations

Bromocriptine induces marked locomotor stimulation in dopamine-depleted mice when D-1 dopamine receptors are stimulated with SKF38393

1986 • 121 citations

Tremor and Involuntary Movements in Monkeys: Effect of L-Dopa and of a Dopamine Receptor Stimulating Agent

1973 • 96 citations

D1 and D2 dopamine agonist synergism: separate sites of action?

1987 • 95 citations

The motor effects of bromocriptine ? a review

1988 • 77 citations

Nigral D1 and striatal D2 receptors mediate the behavioral effects of dopamine agonists

1990 • 74 citations

Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.

1988 • 62 citations

Hypothesis: Bromocriptine lacks intrinsic dopamine receptor stimulating properties

1985 • 24 citations

Further studies on the interaction between bromocriptine and SKF38393 in reserpine and alpha methyl-para-tyrosine-treated mice

1988 • 18 citations

Combined L-Dopa and Bromocriptine Therapy for Parkinsonʼs Disease

1987 • 11 citations